Feed

28/03/2023
European Par­lia­ment and Coun­cil ready to start ne­go­ti­ations on EU Data...
In Feb­ru­ary 2022 the European Com­mis­sion presen­ted its pro­pos­al for the EU Data Act, which – if ad­op­ted - will in­tro­duce a far-reach­ing leg­al re­gime on ac­cess to and use of non-per­son­al data in the...
27/03/2023
The Private Com­pet­i­tion En­force­ment Re­view I Aus­tria Chapter
16th Edi­tion
23/03/2023
CMS ad­vises AL­PLA on joint ven­ture with In­den Pharm
Press re­lease - 22.03.2023An in­ter­na­tion­al team of ex­perts from CMS ad­vised the AL­PLA Group on es­tab­lish­ing a joint ven­ture with the Span­ish pack­aging com­pany In­den Pharma. The core CMS Vi­enna team, led by Al­ex­an­der Rakosi, in­cluded Flori­an May­er and Anna Hiegel­sper­ger.   The AL­PLA Group and In­den Pharma have strengthened their pres­ence in the phar­ma­ceut­ic­al mar­ket by found­ing a joint ven­ture. AL­PLA Pharma is con­trib­ut­ing pro­duc­tion sites in Greece and Po­land to the co­oper­a­tion and In­den Pharma two plants in Spain. To­geth­er they plan to set up a site in Ger­many and triple their pro­duc­tion over the next five years. Such cross-bor­der joint ven­ture pro­jects present nu­mer­ous leg­al chal­lenges, whose suc­cess­ful im­ple­ment­a­tion re­quires seam­less co­oper­a­tion between in­ter­na­tion­ally ex­per­i­enced teams from vari­ous prac­tice groups and jur­is­dic­tions. The ex­pert team for the cur­rent AL­PLA deal in­cluded law­yers from CMS of­fices in Aus­tria, Spain, Ger­many and Po­land.Al­ex­an­der Rakosi, Part­ner at CMS Vi­enna and re­spons­ible for the suc­cess­ful con­clu­sion of the joint ven­ture says: "Cross-bor­der tech­no­logy and know-how trans­fer are be­com­ing in­creas­ingly im­port­ant for our cli­ents’ sus­tain­able eco­nom­ic suc­cess. We are there­fore de­lighted to have made a valu­able con­tri­bu­tion to this deal with our glob­al CMS net­work, our in­ter­na­tion­al ex­per­i­ence and our in-depth ex­pert­ise on cross-bor­der deals."The CMS Aus­tria team con­sisted of cor­por­ate/M&A ex­perts Al­ex­an­der Rakosi, Flori­an May­er, Anna Hiegel­sper­ger, Livia Land­sk­ron, Ra­mona Mu­jan­ovic, Re­becca Herl­itz, Rupert Riedl and Han­nah Gi­er­linger. The In­tel­lec­tu­al Prop­erty de­part­ment was rep­res­en­ted by Hans Le­der­er. Di­eter Zand­ler, Vanessa Hor­aceck and Stefan Sottner were deal­ing with an­ti­trust and com­pet­i­tion law is­sues.The CMS Spain team, led by Lu­is Miguel De Di­os and Jorge Per­is Hev­ia, also in­cluded cor­por­ate/M&A ex­perts Ana Vázquez Re­cio, Lucía Signes de Mesa and Saphira Mouza­yek. Víct­or San­juán Mira, María José Ramos Aguilar, Guillermo Gar­cía Diéguez, Irene San Martín Gar­cía and Ri­cardo Gómez-Barreda de la Gándara were also in­volved in the due di­li­gence pro­cess. Tax law ex­pert­ise was provided by Ri­cardo Héct­or and Marta Bur­gos Mur­illo.The CMS Ger­many team in­cluded Malte Bruhns, Laura Christin Stein, Christin Fisc­her and Mor­itz Zie­g­ler.The CMS Po­land team con­sisted of Blazej Zagor­ski, Joanna Bia­loskor­ska and Aleksandra Da­lecka.
23/03/2023
European Pat­ent Of­fice (EPO) dig­ging its heals in over the need for de­scrip­tion...
As a com­ple­ment to the 10th edi­tion of the EPO "Case Law of the Boards of Ap­peal" (CLB), the EPO has pub­lished an An­nu­al Re­view con­tain­ing sum­mar­ies of de­cisions from 2022. The re­view provides a them­at­ic...
22/03/2023
European Pat­ent Of­fice (EPO) level of dis­clos­ure re­quired for an­ti­bod­ies...
As a com­ple­ment to the 10th edi­tion of the EPO "Case Law of the Boards of Ap­peal" (CLB), the EPO has pub­lished an An­nu­al Re­view con­tain­ing sum­mar­ies of de­cisions from 2022. The re­view provides a them­at­ic...
22/03/2023
CMS European M&A Study 2023
The CMS Cor­por­ate/M&A Group is pleased to launch the 15th edi­tion of the European M&A Study
21/03/2023
Is a pa­tient in a clin­ic­al tri­al con­sidered to be a mem­ber of the pub­lic...
In T 0670/20, the ques­tion was wheth­er the in­tern­al struc­ture of medi­cin­al tab­lets had been made avail­able to the pub­lic by pa­tients tak­ing part in clin­ic­al tri­als in­volving ad­min­is­tra­tion of the tab­lets...
21/03/2023
Di­git­al health apps and telemedi­cine in Aus­tria
Di­git­al Health Apps/Soft­ware 1. How is the soft­ware with­in di­git­al health apps clas­si­fied in your jur­is­dic­tion, and what reg­u­la­tion(s) ap­ply? 1.1 Is it con­sidered a “med­ic­al device” or a “product”...
Comparable
21/03/2023
Whis­tleblower pro­tec­tion and re­port­ing chan­nels in Aus­tria
1. Is there a law on whis­tleblow­ing in your coun­try? There is no law on whis­tleblow­ing. 2. Does loc­al law re­quire private en­tit­ies to es­tab­lish a whis­tleblow­ing sys­tem? (If so, which private en­tit­ies?)...
Comparable
20/03/2023
Out with the old, in with the new? Con­sid­er­a­tions for pat­entees in opt­ing...
So far in this series of blog posts, we began with an art­icle that high­lighted some of the key changes between the cur­rent European sys­tem of pat­ent pro­sec­u­tion and en­force­ment and the new Unit­ary Pat­ent...
20/03/2023
UK An­nounces it will be­come a party to the Singa­pore Con­ven­tion on Me­di­ation
It has been an­nounced that the UK will be­come a party to the United Na­tions Con­ven­tion on In­ter­na­tion­al Set­tle­ment Agree­ments Res­ult­ing from Me­di­ation (the “Singa­pore Con­ven­tion”), as an “im­port­ant...
17/03/2023
In­ter­Di­git­al v Len­ovo – High Court sets glob­al FRAND li­cence terms
The UK High Court has handed down its de­cision in the FRAND tri­al of the In­ter­Di­git­al v Len­ovo lit­ig­a­tion. It con­cerned In­ter­Di­git­al, an Amer­ic­an com­pany hold­ing pat­ents rel­ev­ant to 3G, 4G and 5G tech­no­logy...